Resource Room

Press releases


BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations


BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-Line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma


QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia


Ivy Brain Tumor Center and BridgeBio Subsidiary, QED Therapeutics, Announce Collaboration to Advance Cancer Research and Treatment Options


QED Therapeutics Presents New Data on the Potential for Infigratinib to Treat Upper Tract Urothelial Carcinoma


Preclinical Data Demonstrates the Potential of QED Therapeutics’ Infigratinib in Multiple FGFR+ Tumor Types


QED Therapeutics Announces a Collaboration with Foundation Medicine to Develop Companion Diagnostics for Infigratinib


QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress


QED Tx – A New Company Working on a Treatment for Achondroplasia


BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million in Initial Financing

Infigratinib scientific resources


Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Javle M et al. Presented at the American Society of Clinical Oncology 2019 Annual Meeting; May 31-June 4, 2019; Chicago, IL.


Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results
Dizman N et al. Presented at the American Society of Clinical Oncology 2019 Annual Meeting; May 31-June 4, 2019; Chicago, IL.


A phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle M et al. Presented at the European Society for Medical Oncology 2018 Congress; October 19-23, 2018; Munich, Germany.


Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Pal SK et al. Published in Cancer Discovery.


Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model
Komla-Ebri D et al. Published in The Journal of Clinical Investigation.

More about FGFR and FGFR-driven diseases


About biliary cancer
Dana-Farber Cancer Institute website.


Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype
Jain A et al. Published in JCO Precision Oncology.


Comprehensive genomic characterization of upper tract urothelial carcinoma
Moss TJ et al. Published in European Urology.


Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Sia D et al. Published in Nature Communications.


Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles MA, Hurst CD. Published in Nature Reviews Cancer.


Second-line chemotherapy in advanced biliary cancer: a systematic review
Lamarca A et al. Published in Annals of Oncology.

  • Sign Up

    Stay up to date.

    Receive updates on the development of infigratinib and breaking news from QED Therapeutics.

    *Required fields.

  • Communication Agreement

    By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.

  • This field is for validation purposes and should be left unchanged.

Contact Us

75 Federal Street
San Francisco, CA 94107